Back to top
more

Dynavax Technologies (DVAX)

(Delayed Data from NSDQ)

$10.43 USD

10.43
1,551,340

+0.15 (1.46%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $10.43 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Viatris (VTRS) Q3 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q3 earnings but misses sales estimates as fluctuations in foreign exchange rates continue to impact results. The company reaffirms guidance.

Wall Street Analysts See a 154% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 154.4% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Dynavax Technologies (DVAX) Recently Broke Out Above the 200-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 200-day simple moving average, good things could be on the horizon. How should investors react?

Best Value Stocks to Buy for November 7th

by Zacks Equity Research

HDSN, CWBC and DVAX made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2022.

Bausch (BHC) Q3 Earnings & Sales Miss, Guidance Lowered

by Zacks Equity Research

Bausch (BHC) Q3 earnings and sales decline year over year due to the unfavorable impact of foreign exchange rates. The company also lowers its annual guidance.

Dynavax Technologies (DVAX) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 30.30% and 11.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised

by Zacks Equity Research

Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.

Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised

by Zacks Equity Research

Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.

Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y

by Zacks Equity Research

Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.

Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates

by Zacks Equity Research

Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.

Dynavax Technologies (DVAX) Recently Broke Out Above the 50-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?

Dynavax Technologies (DVAX) Crossed Above the 20-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Does Dynavax Technologies (DVAX) Have the Potential to Rally 210% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 210.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Should Value Investors Buy Dynavax Technologies (DVAX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales

by Zacks Equity Research

Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.

Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer

by Zacks Equity Research

Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.

Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion

by Zacks Equity Research

Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.

Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review

by Zacks Equity Research

Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review.

Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv

by Zacks Equity Research

Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.

Rigel (RIGL) to Not Pursue the WAIHA Program, Cut Jobs

by Zacks Equity Research

Rigel (RIGL) decides to back out from the label expansion of fostamatinib for the treatment of patients with warm autoimmune hemolytic anemia (wAIHA) following the FDA???s review.

Encompass Health (EHC), Piedmont Tie Up to Better Serve Georgia

by Zacks Equity Research

Encompass Health (EHC) collaborates with Piedmont to construct a 40-bed inpatient rehabilitation hospital in Georgia to serve the healthcare needs of the Georgian communities more effectively.

Vir Biotechnology (VIR) Gains 11% This Week on BARDA Contract

by Zacks Equity Research

VIR shares gain following a multi-year contract from BARDA for the development of influenza and other emerging infectious disease or medical countermeasure candidates.

Provention (PRVB) Up on Deal With Sanofi for Diabetes Drug

by Zacks Equity Research

Provention (PRVB) collaborates with Sanofi for the commercialization of lead investigational drug candidate teplizumab.

Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amylyx (AMLX) Secures the FDA's Approval for ALS Drug

by Zacks Equity Research

Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.